- ACAD Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
ACADIA Pharmaceuticals (ACAD) 8-K20 Jul 20ACADIA Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZIDĀ®Ā (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related PsychosisFinancial data
Company Profile